Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Mark Heaney(Immunovaccine (Canada)), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Vesna Najfeld, Rona Singer Weinberg(University of North Carolina at Chapel Hill), Kamal Menghrajani(Memorial Sloan Kettering Cancer Center), Marina Kremyanskaya(Tisch Cancer Institute), John Mascarenhas(Tisch Hospital), Leah Price(Cwm Taf University Health Board), Amylou C. Dueck(Mayo Clinic in Arizona), Elizabeth O. Hexner(University of Pennsylvania), Camille N. Abboud(Washington University in St. Louis), Judith D. Goldberg(New York University), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Lonette Sandy(Icahn School of Medicine at Mount Sinai)
Cited by 61
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k